Merck
VC Fund
Kenilworth, United States
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases. The company is driven by a mission to discover, develop, and provide innovative products and services that save and improve lives.
- Total investments:
- 30
- Last investment:
- Lead investor:
- 30%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Merck invests in
Stages Merck invests in
Countries Merck invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2.6M–$3.3M
- Series A
- $7.8M–$120M
Investment Focus
Industry
- Health Care 17 (57%)
- Biotechnology 17 (57%)
- Medical 9 (30%)
- Therapeutics 7 (23%)
- Genetics 5 (17%)
Stage
- Series A 6 (20%)
- Funding Round 5 (17%)
- Seed 3 (10%)
- Series B 3 (10%)
- Series C 2 (7%)
Country
- United States 19 (63%)
- Canada 2 (7%)
- China 1 (3%)
- India 1 (3%)
- Mexico 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Charles Pigneri
Associate Director Regional Marketing-RML
|
Associate Director Regional Marketing-RML | Total investments: 0 | Find email | |
Fiona Marshall
Senior Vice President Head of Discovery Sciences and Translational Medicine
|
Senior Vice President Head of Discovery Sciences and Translational Medicine | Total investments: 0 | Find email | |
Pamela Craig
Member of The Board of Directors
|
Member of The Board of Directors | Total investments: 0 | Find email | |
Peter Dudek
President & Managing Partner, MRL Ventures Fund
|
President & Managing Partner, MRL Ventures Fund | Total investments: 5 | Find email | |
Seth Staples
Senior Scientist, Vaccine Process Development & Commercialization
|
Senior Scientist, Vaccine Process Development & Commercialization | Total investments: 0 | Find email | |
| See all 16 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Saturnus Bio
|
Saturnus Bio is a precision cardiology company utilizing targeted gene modulation to address rare mono genetic cardiomyopathies with significant unmet need. | Corporate Round / Jun 23, 2026 | |
Solve Therapeutics
|
Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics. The company was founded in 2021 and is headquartered in Belmont, California. | $120M / Series A / Nov 17, 2025 | |
HD
|
HD is a healthcare and surgery marketplace, powering over 1,500+ healthcare providers including some of the biggest hospitals. HD connects patients to hospitals, clinics, operating rooms, and surgeons while offering healthcare financing solutions to increase access to affordable care and surgeries. To date, over 250,000 patients have benefited frommore accessible and affordable healthcare and surgeries through the company's platform. | $7.8M / Series A / Feb 12, 2025 | |
Personalis
|
Personalis combines both the technology of sequencing and interpretation, with an extensive history of peer-reviewed publication and commercial success. It is providing an extensive molecular view of a patient’s tumor and characterizes its interplay with the immune system. It aids in the development of safer, effective precision cancer therapies,immunotherapies, and personalized medicines. | $50M / Post-IPO Equity / Dec 19, 2024 | |
Friends of Puerto Rico
|
Friends of Puerto Rico is a nonpartisan, non-profit social impact group that advocates for economic growth. and education through result-oriented entrepreneurial ventures centered on sustainability and self-sufficiency. | $190K / Grant / May 27, 2024 | |
Oatmeal Health
|
Oatmeal Health is an AI lung cancer diagnostic company that plugs directly into partners’ CADe/PACS systems, turning routine CT scans into reimbursable malignancy‑risk reads under CPT 0721T/0722T without changing radiologist workflow. By layering a nodule‑level, longitudinal risk score on top of existing detection tools, we reduce falsepositives and unnecessary biopsies while creating a new $650‑per‑scan revenue line for imaging centers and health systems. We use joint-venture agreements with platforms like Coreline, so a single integration unlocks entire hospital networks rather than a site-by-site sales model. | $175K / Non-equity Assistance / Mar 15, 2024 | |
Prognos Health
|
Prognos Health is a leading health tech company that is pushing the boundaries of healthcare analytics. The company’s platform, prognosFACTOR, has the power to query billions of lab and health records on more than 325 million de-identified patients to answer clinically-focused healthcare questions in minutes, not months. The platform enables thequerying and purchasing of patient-centric, HIPAA-Compliant healthcare data from the Prognos Marketplace to address diverse applications, including cohort design, patient journey studies, health outcomes and more. Customers include 25 of the top 30 pharmaceutical manufacturers and three of the top five payers. | $23.3M / May 04, 2023 | |
Mamotest
|
Mamotest is a data-driven patient end-to-end solution defeating breast cancer. It goes from awareness and high-quality imaging diagnosis to patient journey follow-up. We collect medical and clinical data and care for psychological and socio-economic data. That broader scope with 100% patient traceability allows us to put vital information in thehands of global business and policy decision-makers, giving them the power to save hundreds of thousands of women's lives. | $3.3M / Seed / Mar 27, 2023 | |
Qure AI
|
At Qure.ai their mission is to make healthcare affordable and accessible using the power of artificial intelligence. They build deep learning solutions that aid physicians with routine diagnosis and treatment, allowing them to spend more time with patients. | $40M / Series C / Mar 29, 2022 | |
Seagen
|
Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates invarious stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington. | $1B / Post-IPO Equity / Sep 14, 2020 | |
| See all 30 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Merck invest in?
Merck invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Funding Round stage. Most of the 30 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Merck's check size?
Merck typically joins rounds of $2.6M–$3.3M at Seed and $7.8M–$120M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Merck participates in.
How do I contact Merck?
Public channels for Merck include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Merck?
The team at Merck includes Charles Pigneri (Associate Director Regional Marketing-RML), Fiona Marshall (Senior Vice President Head of Discovery Sciences and Translational Medicine) and Pamela Craig (Member of The Board of Directors), among 16 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
